Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors

NCT03895970 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Liver Neoplasm Malignant Primary
Cholangiocarcinoma
Combinational Immunotherapy
Biomarker

Interventions

DRUG: Lenvatinib plus Pembrolizumab

Sponsor

Peking Union Medical College Hospital